NCT06886971Recruiting
Strategies to AchieVe Viral Suppression for Youth With HIV
Strategies to AchieVe Viral Suppression for Youth With HIV (The SAVVY Study)
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression (VS), when compared to other populations likely related to multi-layered challenges (social determinants, cognitive development), system, and biomedical challenges including the reliance on oral ART as the only choice for HIV treatment. Given that approximately 1/3 of AHIV despite being in care fail to attain or sustain VS with resultant individual and public health risk, there is a need to develop real-world implementable interventions that can improve the participants virologic outcomes. The Strategies to AchieVe Viral Suppression for Youth with HIV (SAVVY) Study aims to 1) optimize personal ART choice by using the HIV-ASSIST clinical program to inform CHOICE counseling regarding an AHIV's preferred approach, including the possibility of long-acting injectable ART (LAI-ART); 2) facilitate access to the participants preferred choice through deploying a focused team to navigate barriers to attaining LAI-ART; and 3) decipher and address the patient, provider, and systemic barriers to the uptake and routinization of LAI-ART among AHIV by applying an implementation science framework and assessing cost-effectiveness providing critical data to support comprehensive approaches to optimizing ART and VS for AHIV, a key population identified in the Ending the HIV Epidemic in the United States Initiative.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 288 (estimated)
- First submitted
- 14 Mar 2025
- Start date
- 10 Nov 2024
- Primary completion date
- 15 Nov 2027
- Lead sponsor
- Johns Hopkins University
- Diseases
- HIV
- NCT number
- NCT06886971
What you commit to
- Study type: Interventional
- Planned participants: 288
- From 10 Nov 2024 to the primary completion date, 15 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Relevant drug resistance mutations (per medical record) that compromises activity of Cabotegravir (CBG) + rilpivirine (RPV)
- disallowed medications,
Other illness
- severe illness/hospitalization at the time of enrollment,
Other
- pregnancy.
- Mental health, cognitive, or behavioral dysfunction that in the opinion of the site PI would impair participation;
- plan to move away in the next 12 months.
Who the study is looking for
- prescribed ART,
- willing to sign informed consent (including communication with one's primary HIV provider)
Age in the registry: 12 years to 30 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins University Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.